Suppr超能文献

干细胞移植期间口腔黏膜炎的认识与管理进展

Advances in the understanding and management of mucositis during stem cell transplantation.

作者信息

Bowen Joanne M, Wardill Hannah R

机构信息

aAdelaide Medical School, University of Adelaide bCentre for Nutrition and Gastrointestinal Disease, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

出版信息

Curr Opin Support Palliat Care. 2017 Dec;11(4):341-346. doi: 10.1097/SPC.0000000000000310.

Abstract

PURPOSE OF REVIEW

Mucositis is a severe and common side effect of anticancer treatments, with an incidence of between 40 and 80% depending on the cytotoxic regimen used. The most profound mucositis burden is experienced during conditioning regimens for hematopoietic stem cell transplant (HSCT), where the use of highly mucotoxic agents with or without total body irradiation leads to serious damage throughout the alimentary tract. Currently, the assessment and management of both oral and gastrointestinal mucositis lack authoritative guideline, with recommendations only achieved in narrow clinical scenarios. This review provides a brief overview of current management guidelines for mucositis in both adult and pediatric patients receiving HSCT, highlights recent advances in mucositis prevention and discusses future research avenues.

RECENT FINDINGS

The Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO) guidelines for the prevention of mucositis in HSCT are scarce, with low level laser therapy (photobiomodulation) and palifermin only recommended for oral mucositis. Loperamide and octreotide remain gold-standard for the treatment of diarrhea, despite poor efficacy. Although several interventions have been trialled in pediatric cohorts, no recommendations currently exist for children receiving high-dose chemotherapy or total body irradiation for HSCT.

SUMMARY

HSCT continues to be associated with mucositis, which impacts on patients' ability and willingness to receive engraftment, and worsens clinical outcome. Research into the prevention and treatment of mucositis in this setting remains limited, with an overwhelming amount of small, single-center studies that fail to achieve a sufficient level of evidence that warrant recommendation(s). As such, our ability to manage mucotoxic side effects of high-dose chemotherapy and irradiation is limited, particularly in children.

摘要

综述目的

黏膜炎是抗癌治疗中一种严重且常见的副作用,根据所使用的细胞毒性方案不同,其发生率在40%至80%之间。在造血干细胞移植(HSCT)的预处理方案期间,黏膜炎负担最为严重,在此过程中,使用具有高度黏膜毒性的药物(无论是否联合全身照射)会导致整个消化道受到严重损伤。目前,口腔和胃肠道黏膜炎的评估与管理均缺乏权威性指南,仅在狭窄的临床场景中有相关推荐。本综述简要概述了接受HSCT的成人和儿童患者黏膜炎的当前管理指南,强调了黏膜炎预防方面的最新进展,并讨论了未来的研究方向。

最新发现

多国癌症支持治疗协会和国际口腔肿瘤学会(MASCC/ISOO)关于HSCT中黏膜炎预防的指南较少,仅推荐低强度激光治疗(光生物调节)和帕利夫明用于口腔黏膜炎。尽管疗效不佳,但洛哌丁胺和奥曲肽仍是治疗腹泻的金标准。虽然在儿科队列中已对多种干预措施进行了试验,但目前对于接受高剂量化疗或全身照射以进行HSCT的儿童尚无推荐。

总结

HSCT仍然与黏膜炎相关,这会影响患者接受移植的能力和意愿,并恶化临床结局。在这种情况下,关于黏膜炎预防和治疗的研究仍然有限,大量小型单中心研究未能获得足以支持推荐的证据水平。因此,我们管理高剂量化疗和放疗所致黏膜毒性副作用的能力有限,尤其是在儿童中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验